Cargando…

Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy

There is an urgent need for an immunological correlate of protection against tuberculosis (TB) with which to evaluate candidate TB vaccines in clinical trials. Development of a human challenge model of Mycobacterium tuberculosis (M.tb) could facilitate the detection of such correlate(s). Here we pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minassian, Angela M., Ronan, Edward O., Poyntz, Hazel, Hill, Adrian V. S., McShane, Helen
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101220/ https://www.ncbi.nlm.nih.gov/pubmed/21629699 http://dx.doi.org/10.1371/journal.pone.0019840

Ejemplares similares

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, Ansar A., et al.
Publicado: (2012)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis()
por: Poyntz, Hazel C., et al.
Publicado: (2014)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
por: Rowland, Rosalind, et al.
Publicado: (2013)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data()
por: McShane, Helen, et al.
Publicado: (2014)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
por: Villarreal-Ramos, Bernardo, et al.
Publicado: (2014)

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection
por: Betts, Gareth, et al.
Publicado: (2012)

Cholera Toxin Enhances Vaccine-Induced Protection against Mycobacterium Tuberculosis Challenge in Mice
por: Griffiths, Kristin L., et al.
Publicado: (2013)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, Angela M, et al.
Publicado: (2011)

Editorial Commentary: Understanding BCG Is the Key to Improving It
por: McShane, Helen
Publicado: (2014)

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
por: Stylianou, E., et al.
Publicado: (2015)

Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
por: Tanner, Rachel, et al.
Publicado: (2020)

A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Guérin
por: Minassian, Angela M., et al.
Publicado: (2012)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, Anne, et al.
Publicado: (2017)

Progress and challenges in TB vaccine development
por: Voss, Gerald, et al.
Publicado: (2018)

Towards new TB vaccines
por: Brazier, Benedict, et al.
Publicado: (2020)

The Humoral Immune Response to BCG Vaccination
por: Tanner, Rachel, et al.
Publicado: (2019)

Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c
por: Gunasena, Manuja, et al.
Publicado: (2022)

Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model
por: Matsumiya, Magali, et al.
Publicado: (2015)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
por: Pathan, Ansar A., et al.
Publicado: (2007)

IV BCG Vaccination and Aerosol BCG Revaccination Induce Mycobacteria-Responsive γδ T Cells Associated with Protective Efficacy against M. tb Challenge
por: Morrison, Alexandra L., et al.
Publicado: (2023)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
por: Pathan, Ansar A., et al.
Publicado: (2011)

Social determinants and BCG efficacy: a call for a socio-biological approach to TB prevention
por: Dowd, Jennifer B., et al.
Publicado: (2018)

Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges
por: Morrison, Hazel, et al.
Publicado: (2023)

Aerosol immunisation for TB: matching route of vaccination to route of infection
por: Manjaly Thomas, Zita-Rose, et al.
Publicado: (2015)

TB vaccine development: where are we and why is it so difficult?
por: Wilkie, Morven E M, et al.
Publicado: (2015)

A review of clinical models for the evaluation of human TB vaccines
por: O'Shea, Matthew K., et al.
Publicado: (2016)

Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines
por: Harris, Stephanie A., et al.
Publicado: (2018)

761. Age-Related Incidence of TB Infection Supporting Efficacy of BCG Vaccination
por: Sweeney, Eileen, et al.
Publicado: (2018)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1
por: Fletcher, Helen A., et al.
Publicado: (2008)

Vaccination with BCGΔBCG1419c protects against pulmonary and extrapulmonary TB and is safer than BCG
por: Aceves-Sánchez, Michel de Jesús, et al.
Publicado: (2021)

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
por: Tameris, Michele, et al.
Publicado: (2014)

The BCGΔBCG1419c Vaccine Candidate Reduces Lung Pathology, IL-6, TNF-α, and IL-10 During Chronic TB Infection
por: Flores-Valdez, Mario A., et al.
Publicado: (2018)

A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge
por: Stylianou, Elena, et al.
Publicado: (2023)

Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming
por: Gonçalves, Eduardo DC, et al.
Publicado: (2007)

Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining
por: Smith, Steven G, et al.
Publicado: (2010)

A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
por: Tanner, Rachel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cap6q9vobft8v7oc1a5jcmoh8t